IRIS Accounts Production v24.2.0.383 07557627 Board of Directors 1.1.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh075576272022-12-31075576272024-03-31075576272023-01-012024-03-31075576272021-12-31075576272022-01-012022-12-31075576272022-12-3107557627ns15:EnglandWales2023-01-012024-03-3107557627ns14:PoundSterling2023-01-012024-03-3107557627ns10:Director12023-01-012024-03-3107557627ns10:PrivateLimitedCompanyLtd2023-01-012024-03-3107557627ns10:SmallEntities2023-01-012024-03-3107557627ns10:AuditExempt-NoAccountantsReport2023-01-012024-03-3107557627ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012024-03-3107557627ns10:SmallCompaniesRegimeForAccounts2023-01-012024-03-3107557627ns10:FullAccounts2023-01-012024-03-310755762712023-01-012024-03-3107557627ns10:Director22023-01-012024-03-3107557627ns10:Director32023-01-012024-03-3107557627ns10:RegisteredOffice2023-01-012024-03-3107557627ns5:CurrentFinancialInstruments2024-03-3107557627ns5:CurrentFinancialInstruments2022-12-3107557627ns5:Non-currentFinancialInstruments2024-03-3107557627ns5:Non-currentFinancialInstruments2022-12-3107557627ns5:ShareCapital2024-03-3107557627ns5:ShareCapital2022-12-3107557627ns5:SharePremium2024-03-3107557627ns5:SharePremium2022-12-3107557627ns5:RetainedEarningsAccumulatedLosses2024-03-3107557627ns5:RetainedEarningsAccumulatedLosses2022-12-3107557627ns5:PatentsTrademarksLicencesConcessionsSimilar2023-01-012024-03-3107557627ns5:PlantMachinery2023-01-012024-03-3107557627ns5:IntangibleAssetsOtherThanGoodwill2022-12-3107557627ns5:IntangibleAssetsOtherThanGoodwill2023-01-012024-03-3107557627ns5:IntangibleAssetsOtherThanGoodwill2024-03-3107557627ns5:IntangibleAssetsOtherThanGoodwill2022-12-3107557627ns5:LeaseholdImprovements2022-12-3107557627ns5:PlantMachinery2022-12-3107557627ns5:ComputerEquipment2022-12-3107557627ns5:LeaseholdImprovements2023-01-012024-03-3107557627ns5:ComputerEquipment2023-01-012024-03-3107557627ns5:LeaseholdImprovements2024-03-3107557627ns5:PlantMachinery2024-03-3107557627ns5:ComputerEquipment2024-03-3107557627ns5:LeaseholdImprovements2022-12-3107557627ns5:PlantMachinery2022-12-3107557627ns5:ComputerEquipment2022-12-3107557627ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3107557627ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3107557627ns5:CurrentFinancialInstruments2023-01-012024-03-3107557627ns5:Secured2024-03-3107557627ns5:Secured2022-12-31
REGISTERED NUMBER: 07557627 (England and Wales)















Unaudited Financial Statements

For The Period 1 January 2023 to 31 March 2024

for

Ultra Biotecs Limited

Ultra Biotecs Limited (Registered number: 07557627)

Contents of the Financial Statements
For The Period 1 January 2023 to 31 March 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Ultra Biotecs Limited

Company Information
For The Period 1 January 2023 to 31 March 2024







DIRECTORS: Mr M R Snowball
Mr S M Gordon
Mr P E Barr





REGISTERED OFFICE: 7 Billing Road
Northampton
NORTHAMPTONSHIRE
NN1 5AN





REGISTERED NUMBER: 07557627 (England and Wales)





ACCOUNTANTS: Cochran, Harris & Clarke Ltd
7 Billing Road
Northampton
NORTHAMPTONSHIRE
NN1 5AN

Ultra Biotecs Limited (Registered number: 07557627)

Balance Sheet
31 March 2024

2024 2022
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 62,952 51,000
Tangible assets 5 775,552 499,491
838,504 550,491

CURRENT ASSETS
Debtors 6 5,400 31,856
Cash at bank and in hand 352,078 293,747
357,478 325,603
CREDITORS
Amounts falling due within one year 7 406,758 178,173
NET CURRENT (LIABILITIES)/ASSETS (49,280 ) 147,430
TOTAL ASSETS LESS CURRENT
LIABILITIES

789,224

697,921

CREDITORS
Amounts falling due after more than one year 8 158,420 440,855
NET ASSETS 630,804 257,066

CAPITAL AND RESERVES
Called up share capital 26,004 26,004
Share premium 2,101,966 2,101,966
Retained earnings (1,497,166 ) (1,870,904 )
SHAREHOLDERS' FUNDS 630,804 257,066

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ultra Biotecs Limited (Registered number: 07557627)

Balance Sheet - continued
31 March 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 October 2024 and were signed on its behalf by:





Mr P E Barr - Director


Ultra Biotecs Limited (Registered number: 07557627)

Notes to the Financial Statements
For The Period 1 January 2023 to 31 March 2024


1. STATUTORY INFORMATION

Ultra Biotecs Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis. This is dependant upon the continuing support of the shareholders.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover from operating leases granted to customers is accounted for on a straight line basis over the period of the lease

Intangible assets
Patents purchased by the company are amortised individually over their anticipated economic life. The anticipated economic life of the existing purchased patents is five years.

Applications for patents resulting from research and development expenditure is written off unless the patent has a readily ascertainable market value in accordance with accounting standard FRS10.

The company has capitalised costs associated with developing patents. The costs are being written off over ten years commencing from January 2019.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on cost, 10% on cost, Over the length of time of the lease and Straight line over 3 years

Financial instruments
The company only enters into basic financial instruments that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in profit and loss.

Financial assets and liabilities are offset and the ent amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Ultra Biotecs Limited (Registered number: 07557627)

Notes to the Financial Statements - continued
For The Period 1 January 2023 to 31 March 2024


2. ACCOUNTING POLICIES - continued

Research and development
With the exception of costs incurred in respect of the development of prototype plant, expenditure on research and development is written off in the year in which it is incurred

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 6 (2022 - 6 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 January 2023 126,600
Additions 28,221
At 31 March 2024 154,821
AMORTISATION
At 1 January 2023 75,600
Charge for period 16,269
At 31 March 2024 91,869
NET BOOK VALUE
At 31 March 2024 62,952
At 31 December 2022 51,000

Ultra Biotecs Limited (Registered number: 07557627)

Notes to the Financial Statements - continued
For The Period 1 January 2023 to 31 March 2024


5. TANGIBLE FIXED ASSETS
Plant and Computer
Prototypes machinery equipment Totals
£    £    £    £   
COST
At 1 January 2023 1,118,215 160,747 5,434 1,284,396
Additions 292,954 - - 292,954
At 31 March 2024 1,411,169 160,747 5,434 1,577,350
DEPRECIATION
At 1 January 2023 662,336 119,731 2,838 784,905
Charge for period - 15,279 1,614 16,893
At 31 March 2024 662,336 135,010 4,452 801,798
NET BOOK VALUE
At 31 March 2024 748,833 25,737 982 775,552
At 31 December 2022 455,879 41,016 2,596 499,491

Expenditure on the current prototype is ongoing and depreciation will commence once the prototype has been completed.

Tangible fixed assets include assets leased to customers. The cost of leased assets amounts to £117,247 (2022: £117,247) with a net book value of £nil (2022: £9,841). Depreciation charged on assets leased to customers for the period was £9,841 (2022: £23,592).

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2022
£    £   
Trade debtors 5,400 -
Other debtors - 31,856
5,400 31,856

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2022
£    £   
Trade creditors 4,587 4,853
Taxation and social security 28,117 6,556
Other creditors 374,054 166,764
406,758 178,173

Other creditors includes an amount of £89,444 (2022: £27,921) in respect of deferred income. The deferred income relates to income from operating leases that extend beyond the accounting period.

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2024 2022
£    £   
Other creditors 158,420 440,855

Ultra Biotecs Limited (Registered number: 07557627)

Notes to the Financial Statements - continued
For The Period 1 January 2023 to 31 March 2024


9. SECURED DEBTS

The following secured debts are included within creditors:

2024 2022
£    £   
Other loans 410,927 540,007

These amounts are secured by a fixed and floating charge over all property or undertaking of the company.

10. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

M R Snowball and P E Barr have advanced monies to the company. At the balance sheet date the amount due to M R Snowball is £213 (2022: £213).and to P E Barr is £98 (2022: £98)